OpenAlex
PricingAboutJobs
Log inGet started
Work

Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial

HTML

Year: 2020
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Source: The Lancet. Gastroenterology & hepatology
DOI: 10.1016/s2468-1253(20)30186-2
Authors: Rohit Loomba, Erin Morgan, Lynnetta Watts, Shuting Xia, Lisa A Hannan, Richard S Geary, Brenda F Baker, Sanjay Bhanot
Institutions: University of California San Diego, Ionis Pharmaceuticals (United States)
Language: English

Topic: Liver Disease Diagnosis and Treatment
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Keywords: DGAT2, antisense oligonucleotides, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, hepatic steatosis, liver fat reduction, type 2 diabetes, triglyceride synthesis, proton density fat fraction, pharmacodynamics
SDG: Good health and well-being

Open Access status: closed

Funder: National Institute of Diabetes and Digestive and Kidney Diseases
Awards: Non-invasive screening of diabetics for advanced fibrosis due to NAFLD, Ancillary Studies of NAFLD and NASH in HIV infected Adults, QUS Technology for Diagnosis and Grading of Hepatic Steatosis in NAFLD, San Diego Digestive Diseases Research Center
OpenAlex ID: W3035704995
FWCI: 7.106
Cites: 38
Cited by: 118
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security